ECSP19082184A - Anticuerpos agonistas contra btla y sus usos - Google Patents

Anticuerpos agonistas contra btla y sus usos

Info

Publication number
ECSP19082184A
ECSP19082184A ECSENADI201982184A ECDI201982184A ECSP19082184A EC SP19082184 A ECSP19082184 A EC SP19082184A EC SENADI201982184 A ECSENADI201982184 A EC SENADI201982184A EC DI201982184 A ECDI201982184 A EC DI201982184A EC SP19082184 A ECSP19082184 A EC SP19082184A
Authority
EC
Ecuador
Prior art keywords
antibodies against
agonist antibodies
btla
against btla
antibodies
Prior art date
Application number
ECSENADI201982184A
Other languages
English (en)
Inventor
Shane Krummen Atwell
Andrew Charles Vendel
Victor H Obungu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP19082184A publication Critical patent/ECSP19082184A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan anticuerpos que se fijan a BTLA, y métodos para usarlos, en donde dichos anticuerpos son útiles como agentes para tratar afecciones asociadas a la enfermedad autoinmunitaria, que incluyen el tratamiento de lupus.
ECSENADI201982184A 2017-05-19 2019-11-18 Anticuerpos agonistas contra btla y sus usos ECSP19082184A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762508510P 2017-05-19 2017-05-19

Publications (1)

Publication Number Publication Date
ECSP19082184A true ECSP19082184A (es) 2019-11-30

Family

ID=62245543

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201982184A ECSP19082184A (es) 2017-05-19 2019-11-18 Anticuerpos agonistas contra btla y sus usos

Country Status (26)

Country Link
US (2) US10604573B2 (es)
EP (1) EP3625257A1 (es)
JP (2) JP6790304B2 (es)
KR (3) KR20210106033A (es)
CN (3) CN117402244A (es)
AR (1) AR111752A1 (es)
AU (2) AU2018269585B2 (es)
BR (1) BR112019021547A2 (es)
CA (2) CA3064518A1 (es)
CL (1) CL2019003215A1 (es)
CO (1) CO2019012756A2 (es)
CR (1) CR20190521A (es)
DO (1) DOP2019000293A (es)
EA (1) EA201992460A1 (es)
EC (1) ECSP19082184A (es)
JO (1) JOP20190261A1 (es)
MA (1) MA49133A (es)
MX (1) MX381033B (es)
MY (2) MY198277A (es)
NZ (1) NZ758360A (es)
PE (1) PE20191843A1 (es)
PH (1) PH12019502575A1 (es)
SA (1) SA519410534B1 (es)
TW (4) TWI747043B (es)
WO (1) WO2018213113A1 (es)
ZA (1) ZA201906954B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820554D0 (en) * 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
JP7551744B2 (ja) 2019-10-15 2024-09-17 イーライ リリー アンド カンパニー 組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株
GB202008860D0 (en) * 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
JP2023546713A (ja) * 2020-10-23 2023-11-07 アナプティスバイオ インコーポレイティッド Ｂ及びｔリンパ球アテニュエータ（ｂｔｌａ）調節因子及びその使用方法
IL314373A (en) * 2022-01-29 2024-09-01 Hifibio Inc ANTI-BTLA antibodies and their use for cancer treatment
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024243594A1 (en) * 2023-05-25 2024-11-28 Anaptysbio, Inc. Btla agonist for mudulation of dendritic cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
JP2006515167A (ja) * 2002-10-25 2006-05-25 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
CL2007003291A1 (es) * 2006-11-15 2008-07-04 Medarex Inc Anticuerpo monoclonal humano aislado que enlaza la proteina btla o fragmentos del mismo; acido nucleico que lo codifica; metodo de produccion; composicion e inmunoconjugado que los comprende; y metodo para inhibir el crecimiento de celulas de tumor e
CA2769473A1 (en) * 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
US9533039B2 (en) * 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
WO2014018931A1 (en) * 2012-07-26 2014-01-30 The General Hospital Corporation Methods and compositions for treating autoimmune disease
WO2014183885A1 (en) * 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
EP3288587A4 (en) * 2015-04-29 2018-09-12 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
US11253590B2 (en) 2015-12-02 2022-02-22 Stsciences, Inc. Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)

Also Published As

Publication number Publication date
CN110621699A (zh) 2019-12-27
SA519410534B1 (ar) 2023-11-08
KR102294051B1 (ko) 2021-08-27
DOP2019000293A (es) 2019-12-15
TWI677504B (zh) 2019-11-21
CN110621699B (zh) 2023-10-31
PH12019502575A1 (en) 2020-07-13
AU2018269585A1 (en) 2019-10-31
MX381033B (es) 2025-03-12
MY198277A (en) 2023-08-18
JP7072622B2 (ja) 2022-05-20
EP3625257A1 (en) 2020-03-25
CA3184628A1 (en) 2018-11-22
TWI804044B (zh) 2023-06-01
CR20190521A (es) 2020-01-06
EA201992460A1 (ru) 2020-03-18
AU2021277743A1 (en) 2021-12-23
TWI747043B (zh) 2021-11-21
JOP20190261A1 (ar) 2019-11-05
AU2018269585B2 (en) 2021-09-02
CN117402244A (zh) 2024-01-16
US20200239578A1 (en) 2020-07-30
NZ758360A (en) 2022-10-28
TW201904991A (zh) 2019-02-01
CL2019003215A1 (es) 2020-04-13
WO2018213113A1 (en) 2018-11-22
BR112019021547A2 (pt) 2020-05-12
US11396545B2 (en) 2022-07-26
CN117402245A (zh) 2024-01-16
MA49133A (fr) 2020-03-25
JP2020518288A (ja) 2020-06-25
PE20191843A1 (es) 2019-12-31
KR20190140969A (ko) 2019-12-20
JP2021019642A (ja) 2021-02-18
JP6790304B2 (ja) 2020-11-25
KR20220158847A (ko) 2022-12-01
CA3064518A1 (en) 2018-11-22
ZA201906954B (en) 2021-06-30
MX2019013604A (es) 2019-12-18
TW202334237A (zh) 2023-09-01
TW202233681A (zh) 2022-09-01
US10604573B2 (en) 2020-03-31
KR20210106033A (ko) 2021-08-27
MY197425A (en) 2023-06-16
CO2019012756A2 (es) 2020-01-17
AR111752A1 (es) 2019-08-14
US20180334502A1 (en) 2018-11-22
TW201946932A (zh) 2019-12-16

Similar Documents

Publication Publication Date Title
ECSP19082184A (es) Anticuerpos agonistas contra btla y sus usos
CR20190179A (es) Anticuerpos anti-il-33 y usos de estos
UY35417A (es) Anticuerpos dirigidos contra il-33 y sus usos.
CO2017002719A2 (es) Anticuerpos anti-glucagón
CL2017003404A1 (es) Compuestos antibacterianos
AR102712A1 (es) Agonistas parciales del receptor de insulina
ECSP17070399A (es) Anticuerpos contra icos
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
ECSP17063327A (es) Receptores de antígeno quiméricos anti–dll3 y métodos de uso
SV2017005355A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
PE20171556A1 (es) Agentes de union a cd123 y usos de estos
EA201891376A1 (ru) Бензотиофеновые селективные блокаторы эстрогеновых рецепторов
MX2023012740A (es) Anticuerpos antifactor de la coagulacion xi.
BR112017006520A2 (pt) métodos de tratamento do lúpus eritematoso sistêmico usando um anticorpo de domínio direcionado contra cd28
UY35327A (es) ?4,5-dihidro-1,2,4-oxadiazoles disustituidos en 3,5 y composiciones y métodos para controlar plagas de nematodos?.
BR112018067951A2 (pt) moléculas que se ligam a ilt7 e métodos de uso destas
MX2016016664A (es) Metodos para tratar condiciones con anticuerpos que enlazan al receptor de factor 1 estimulador de colonias (csf1r).
AR129996A2 (es) Anticuerpos dirigidos contra il-33 y sus usos
DOP2019000082A (es) Anticuerpos anti-il-33 y usos de los mismos
ECSP17039183A (es) Agonistas parciales del receptor de insulina
AR098780A1 (es) Proceso de obtención de micropartículas de quitosano
AR105316A1 (es) Anticuerpos contra el receptor de transferrina (anti-cd71), anticuerpos anti-cd71 activables y sus métodos de uso